• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

Resistance to imatinib (Gleevec) caused by LYN kinase

Posted on June 24, 2008 by crimsoncanary

Data published in this weeks Journal of the National Cancer Institute shows that activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML)

Filed under: kinase | Tagged: Bcr-Abl, c-kit, Gleevec, Glivec, Imatinib, Novartis, PDGF

« Exelixis begin Phase II trial of multikinase inhibitor XL184 in Glioblastoma Multiforme ImClone begin trial of anti IGF-1R MAb IMC-A12 in combination with Temsirolimus »
  • Calendar

    • June 2008
      M T W T F S S
      « May   Jul »
       1
      2345678
      9101112131415
      16171819202122
      23242526272829
      30  
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer